Overview

A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)

Status:
Completed

Trial end date:
2007-03-01

Target enrollment:

Participant gender:

Summary

This is a phase III, multicenter, randomized, double masked, sham injection-controlled study of the efficacy and safety of intravitreally administered ranibizumab in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration.

Phase:

Phase 3

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Ranibizumab